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Escherichia coli 
as Reservoir 
for Macrolide 
Resistance Genes
Minh Chau Phuc Nguyen, Paul-Louis Woerther, 
Mathilde Bouvet, Antoine Andremont,  
Roland Leclercq, and Annie Canu
The plasmid-borne mph(A) gene that confers resis-
tance to azithromycin and has recently emerged in Shi-
gella sonnei is present in multidrug- and non–multidrug-re-
sistant Escherichia coli isolates from 4 continents. Further 
spread of mph(A) to Shigella and Salmonella spp. may be 
expected.
Macrolides have been regarded for many decades as having good activity and safety for the treatment of 
infections caused by gram-positive cocci. In general, mac-
rolides show modest potency against Enterobacteriaceae. 
Most Shigella and Salmonella spp. pathogens display MICs 
of azithromycin, a macrolide antimicrobial drug, ranging 
from 2 mg/L to 8 mg/L (1). Despite these relatively high 
MICs, azithromycin is an attractive option for several rea-
sons. It can be given once a day and attains high intracellu-
lar concentrations and sufficient concentrations in the colon 
of patients to inhibit Shigella and Salmonella spp. Azithro-
mycin is recommended by the American Academy of Pedi-
atrics for treatment of shigellosis in children (2) and by the 
World Health Organization as a second-line treatment for 
adults (3). It has also been proposed for short-course treat-
ment of typhoid fever (4).
We recently reported an outbreak of shigellosis in 
Paris, France; failure of azithromycin treatment was re-
lated to emergence of plasmid-mediated resistance to mac-
rolides (5). Resistance was related to the expression of a 
macrolide 2′-phosphotransferase encoded by the mph(A) 
gene. Because shigellosis remains a common gastrointesti-
nal disease in both developing and industrialized countries, 
emergence of macrolide resistance may have major public 
health consequences.
Since the early reports by Ochiai (6) and Akiba (7) at 
the end of the 1950s, plasmid-mediated transfer of resis-
tance genes between Escherichia coli and Shigella spp. has 
been reported in several instances (8). Therefore, we hy-
pothesized that E. coli might constitute a major reservoir 
for macrolide resistance genes that could be subsequently 
transferred to Shigella sonnei.
Acquired resistance to macrolides may result from a 
variety of mechanisms of resistance, several of which have 
already been reported in Enterobacteriaceae (9,10). These 
mechanisms include target site modification by methylases 
encoded by erm genes, in particular erm(A), erm(B), and 
erm(C). Macrolides may be inactivated by modifying en-
zymes first reported in Enterobacteriaceae (11,12), e.g., 
esterases encoded by ere(A) or ere(B) genes or phospho-
transferases encoded by mph(A), mph(B), and mph(D) 
genes. The third mechanism is acquisition of efflux pumps, 
mef(A) and msr(A), that have been found essentially in 
gram-positive organisms, although mef(A) has been identi-
fied in gram-negative organisms (10). All of these genes 
confer full cross-resistance between erythromycin and 
azithromycin (9). We aimed to assess the prevalence of ac-
quired resistance to macrolides in commensal and clinical 
isolates of E. coli from various geographic origins and to 
characterize the mechanisms underlying E. coli resistance 
to macrolides.
The Study
A total of 190 E. coli isolates were collected from 5 
countries on 4 continents. Some of these isolates were ob-
tained from populations exposed to low antimicrobial se-
lective pressure; 45 commensal isolates were from feces of 
healthy Wayampi Amerindians in French Guiana, 20 from 
feces of children living in a remote village of Senegal, and 
49 from feces of healthy nurses working in a hospital in 
Paris. Other isolates were obtained from populations hav-
ing received multiple antimicrobial drug treatments; 29 
isolates were from feces of children from Niger hosted in 
a center for nutritional rehabilitation, and 47 isolates were 
producers of extended-spectrum β-lactamase (ESBL) ob-
tained from various clinical samples in hospitalized pa-
tients in Vietnam (n = 37) and France (Hospital of Caen) 
(n = 10).
Susceptibility to 16 antimicrobial drugs was deter-
mined by the disk-diffusion method. MICs of erythromycin 
were determined by the agar dilution technique, and ESBLs 
were detected by the double-disk synergy test, as recom-
mended by the French Society for Microbiology (www.
sfm.asso.fr).
E. coli isolates from French Guiana, Senegal, and Paris 
were susceptible to quinolones, gentamicin, and third-gen-
eration cephalosporins. Resistance to amoxicillin-ticarcil-
lin (by penicillinase production) was detected for 22.2%, 
20.4%, and 40.0% of the isolates obtained from nurses in 
Guiana, Paris, and Senegal, respectively. Coresistance to 
amoxicillin and cotrimoxazole was found for 13%, 14%, 
and 35% of isolates, respectively.
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E. coli and Macrolide Resistance
Multidrug-resistant isolates were commonly obtained 
from Niger natives; 34.4% were resistant to both cefo-
taxime (mostly by ESBL production) and ciprofloxacin, 
and 58.6% to gentamicin. ESBL producers from Vietnam 
and Caen hospital displayed resistance to ciprofloxacin for 
86.5% and 60.0% and resistance to gentamicin for 86.4% 
and 50.0% of isolates, respectively. MICs of erythromycin 
ranged from 16 mg/L to >1,024 mg/L (Table 1; Figure). 
Distribution of MICs of erythromycin was bimodal; mode 
= 64 mg/L for 1 population with low MICs and >1,024 
mg/L for the other population with high MICs (Figure).
MICs differed according to the origin of the isolates. 
Multiple resistance was associated with MICs of erythro-
mycin >256 mg/L with 1 exception: an isolate from Guiana 
was resistant only to amoxicillin and cotrimoxazole (MIC 
of erythromycin, 1,024 mg/L).
We screened for macrolide resistance genes by using 
oligonucleotide primers and PCR conditions (Table 2). 
PCR reactions were performed as follows: an initial dena-
turation step (95oC, 3 min) followed by 30 cycles consist-
ing of denaturation (95oC, 30 s), annealing at a temperature 
depending on the primers used (30 s), elongation (72oC, 30 
s) and a final extension step (72oC, 10 min). Positive and 
negative controls were included in each run.
The mph(A) gene was commonly present in 34 isolates 
(MICs 256 mg/L to >1,024 mg/L). The gene was mostly 
detected in isolates resistant to cefotaxime (27 isolates) but 
also in 4 (21%) of 19 isolates resistant to only amoxicillin 
and cotrimoxazole in different countries. To confirm this 
latter association, we searched for the mph(A) gene in 100 
clinical isolates of E. coli from the Caen hospital coresis-
tant to amoxicillin and cotrimoxazole but susceptible to ce-
fotaxime, which is a common phenotype present in ≈25% 
of E. coli isolates from this hospital. The gene was detected 
in 13 isolates (MIC >256 mg/L), confirming the presence 
of the gene in non–multidrug-resistant E. coli (Table 1). In 
a previous study on the distribution of 7 macrolide resis-
tance genes in gram-negative isolates from the urine and 
oral cavity of healthy children in Portugal, Ojo et al. de-
tected the mph(A) gene in 15 of 26 studied E. coli isolates 
(10). However, the profile of resistance to other antimicro-
bial drugs was not determined.
The other macrolide resistance genes were more 
scarce. The erm(B) gene was detected in 2 isolates (MICs 
>1,024 mg/L) and mph(B) in 2 others (MICs 128 mg/L). In 
4 isolates (MICs >1,024 mg/L), both mph(A) and erm(B) 
were amplified. The 6 other genes, erm(A), erm(C), ere(A), 
ere(B), mef(A), and msr(A), were not detected. In 6 isolates 
with MICs of erythromycin equal to 256 mg/L and 2 with 
MICs of erythromycin equal to 512 mg/L, no resistance 
gene could be amplified, suggesting the presence of other 
macrolide resistance determinants. Distribution of the re-
sistance genes mph(A), erm(B), and mph(B) is shown in 
Table 1 and in the Figure.
Conclusions
The plasmid-borne mph(A) gene detected in S. sonnei 
resistant to azithromycin was the most common macrolide 
resistance gene detected in E. coli collected in 5 countries 
on 4 continents. The gene was mostly detected in isolates 
from patients who had received antimicrobial drugs or had 
been hospitalized, in particular in ESBL producers, but was 
also detected in E. coli isolates coresistant to amoxicillin 
and cotrimoxazole, which are common worldwide. Be-
cause E. coli and Shigella spp. are phylogenetically closely 
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Table 1. MICs of erythromycin and distribution of macrolide resistance genes among 190 Escherichia coli isolates from 5 countries* 
MIC of erythromycin, mg/L Gene, no. (%)† 
E. coli origin (no. isolates) Range MIC50 MIC90 erm(B) mph(A) mph(B) 
French Guiana, Amerindians (45) 32–1,024 64 128 0 1 (2) 0 
Senegal, remote village (20) 64–128 128 128 0 0 0 
Niger, children (29) 64–>1,024 256 >1,024 0 9 (31) 0 
France, healthy nurses (49) 16–256 64 128 0 2 (4) 1 (2) 
France, ESBL isolates (10) 64–1,024 128 1,024 0 3 (30) 1 (10) 
Vietnam, ESBL isolates (37) 32–>1,024 512 >1,024 5 (13.5) 19 (51) 0 
France, hospital isolates resistant to 
ampicillin and cotrimoxazole (100) 
32–>1,024 64 >1,024 1 (1) 13 (13) 0 
*ESBL, extended-spectrum ?-lactamase; MIC50, MIC at which 50% of isolates are inhibited; MIC90, MIC at which 90% of isolates are inhibited. 
†No isolate contained the erm(A), erm(C), ere(A), ere(B), msr(A), or mef(A) genes. 
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Figure. Distribution of MICs of erythromycin for Escherichia coli 
isolates according to the presence of genes resistant to macrolides. 
MIC distribution is shown for all strains (black bars). Solid white 
bars indicate strains containing a macrolide resistance gene: 
erm(B), mph(A), or mph(B). Some isolates may contain 2 genes 
resistant to macrolides.
related species that easily exchange plasmids, further dis-
semination of resistance to macrolides in the latter species 
may be predicted. Also, plasmid-mediated resistance to 
macrolides may emerge in Salmonella spp., which is also a 
target of azithromycin.
Ms Nguyen is pursuing a master’s degree at the University 
of Caen. The focus of her work is the identification of reservoirs 
of macrolide resistance genes.
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Table 2. Oligonucleotide primers used for detection of Escherichia coli macrolide resistance genes 
Target gene Primer Sequence, 5? ? 3? Product size, bp 
Annealing 
temperature, oC 
mph(A) mphAF GTGAGGAGGAGCTTCGCGAG 403 60 
mphAR TGCCGCAGGACTCGGAGGTC   
mph(B) mphBF GATATTAAACAAGTAATCAGAATAG 494 58 
mphBR GCTCTTACTGCATCCATACG   
erm(A) ermAF TCTAAAAAGCATGTAAAAGAAA 533 52 
ermAR CGATACTTTTTGTAGTCCTTC   
erm(B) ermBF GAAAAAGTACTCAACCAAATA 639 45 
ermBR AATTTAAGTACCGTTACT   
erm(C) ermCF TCAAAACATAATATAGATAAA 642 45 
ermCR GCTAATATTGTTTAAATCGTCAAT   
ere(A) ereAF GCCGGTGCTCATGAACTTGAG 420 60 
ereAR CGACTCTATTCGATCAGAGGC   
ere(B) ereBF TTGGAGATACCCAGATTGTAG 537 55 
ereBR GAGCCATAGCTTCAACGC   
mef(A) mefAF AGTATCATTAATCACTAGTGC 345 54 
mefAR TTCTTCTGGTACTAAAAGTGG   
msr(A) msrAF GCACTTATTGGGGGTAATGG 384 58 
msrAR GTCTATAAGTGCTCTATCGTG   
